ArticleACS medicinal chemistry letters2019
In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- Structure and solution biospeciation on tricarbonylrhenium(I) complexes of mercaptopyrimidines with multifaceted biological activity.Metallomics : integrated biometal science · 2026Article
- Rhenium(I) tricarbonyl complexes with 1,10-phenanthroline derivatives: potential anticancer agents for hepatocellular carcinoma.Frontiers in pharmacology · 2026Article
- Synthesis of aACS omega · 2025Article
- Review of Recent Medicinal Applications of Rhenium(I) Tricarbonyl Complexes.International journal of molecular sciences · 2025Review
- Structural and Solution Speciation Studies onACS omega · 2024Article
- Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells andJournal of medicinal chemistry · 2024Article
- Role of Pure Technetium Chemistry: Are There Still Links to Applications in Imaging?Inorganic chemistry · 2023Article
- CuAAC "Click"-Derived Luminescent 2-(2-(4-(4-(Pyridin-2-yl)-1ACS omega · 2023Article
- Rhenium(I) Tricarbonyl Complexes of 1,10-Phenanthroline Derivatives with Unexpectedly High Cytotoxicity.Inorganic chemistry · 2023Article
- Article
- Recent Development of Rhenium-Based Materials in the Application of Diagnosis and Tumor Therapy.Molecules (Basel, Switzerland) · 2023Review
- Mitochondria as a target of third row transition metal-based anticancer complexes.Current opinion in chemical biology · 2023Review
- Evaluation of cytotoxic properties of two fluorescentRSC advances · 2022Article
- Real-time tracking of ER turnover during ERLAD by a rhenium complex via lifetime imaging.National science review · 2022Article
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Naphthalene Exchange in [Re(ηChemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives.Molecules (Basel, Switzerland) · 2022Review
- Label-Free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex.Frontiers in chemistry · 2022Article
- ReAngewandte Chemie (International ed. in English) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The rhenium(I) complex
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.